Antiplatelet medications and their indications in preventing and treating coronary thrombosis

References

• Wright I. Experience with anticoagulants. Circulation 1959; 19: 110–3
   PubMed Web of Science ®Google Scholar
• Craven L. Acetylsalicylic acid, possible preventive of coronary thrombosis. Ann West Med Surg 1950; 4: 95
   PubMedGoogle Scholar
• Craven LL. Experiences with aspirin (acetylsalicylic acid) in the nonspecific prophylaxis of coronary thrombosis. Mississippi Valley Medical Journal 1953; 75: 38–44
   PubMedGoogle Scholar
• Herrick J. Clinical features of sudden obstruction of the coronary arteries. JAMA 1912; 59: 2015–20
   Google Scholar
• DeWood M. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 303: 897–901
   PubMed Web of Science ®Google Scholar
• Davis M, Thomas A. Thrombosis and acute coronary artery lesions in sudden cardiac ischemic death. N Engl J Med 1984; 310: 1137–40
   PubMed Web of Science ®Google Scholar
• Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 1992; 326: 242–50
   PubMed Web of Science ®Google Scholar
• Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med 1992; 326: 310–8
   PubMed Web of Science ®Google Scholar
• Wagner CL, Mascelli MA, Neblock DS, Weisman HF, Coller BS, Jordan RE. Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood 1996; 88: 907–14
   PubMed Web of Science ®Google Scholar
• Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995; 332: 1553–9
   PubMed Web of Science ®Google Scholar
• Gifford R, Feinstein A. A critique of methodology in studies of anticoagulant therapy for acute myocardial infarction. N Engl J Med 1969; 280: 351–7
   PubMed Web of Science ®Google Scholar
• ISIS-2 Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349–60
   PubMed Web of Science ®Google Scholar
• Awtry E, Loscalzo J. Aspirin. Circulation 2000; 101: 1206–18
   PubMed Web of Science ®Google Scholar
• Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 1971; 231: 231–5
   Web of Science ®Google Scholar
• Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982; 69: 1366–72
   PubMed Web of Science ®Google Scholar
• Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy—I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81–106
   PubMed Web of Science ®Google Scholar
• Mills DCB, Puri R, Hu C-J, Minniti C, Grana G, Freedman MD. Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arterioscler Thromb 1992; 12: 430–6
   PubMed Web of Science ®Google Scholar
• Herbert J-M, Dol F, Bernat A, Falotico R, Lale A, Savi P. The antiaggregating and antithrombotic activity of clopidogrel is potentiated by aspirin in several experimental models in the rabbit. Thromb Haemost 1998; 80: 512–8
   PubMed Web of Science ®Google Scholar
• Di Perri T, Pasini FL, Frigerio C, Blardi P, Centini F, Messa GL. Pharmacodynamics of ticlopidine in man in relation to plasma and blood cell concentration. Eur J Clin Pharmacol 1991; 41: 429–34
   PubMed Web of Science ®Google Scholar
• Bachman F, Savcic M, Hauert J, Geudelin B, Kieffer G, Cariou R. Rapid onset of inhibition of ADP-induced platelet aggregation by a loading dose of clopidogrel (abstract). Eur Heart J 1996; 17: 263
   Google Scholar
• Bennett CL, Kiss JE, Weinberg PD, Pinevich AJ, Green D, Kwaan HC. Thrombotic thrombocytopenic purpura after stenting and ticlopidine. Lancet 1998; 352: 1036–7
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Tan WA, Foody JM, Topol EJ. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. JAMA 1999; 281: 806–10
   PubMed Web of Science ®Google Scholar
• Bennett C, Connors J, Carwile J, Moake J, Bell W, Tarantolo S. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000; 342: 1773–7
   PubMed Web of Science ®Google Scholar
• Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. The CATS Group. Lancet 1989; 1: 1216–20
   Web of Science ®Google Scholar
• CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329–39
   PubMed Web of Science ®Google Scholar
• Mascelli M, Lance E, Wagner C. Abciximab (7E3) pharmaco-dynamics demonstrates an extended and gradual recover from GPIIb/IIIa blockade. Circulation 1996; 95: 809–13
   Google Scholar
• Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. The SYMPHONY Investigators. Lancet 2000; 355: 337–45
   PubMedGoogle Scholar
• O'Neill WW, Serruys P, Knudtson M, Van Es GA, Timmis GC, Van der Zwaan C. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. N Engl J Med 2000; 342: 1316–24
   PubMed Web of Science ®Google Scholar
• Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2. Dipyrid-amole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1–13
   PubMed Web of Science ®Google Scholar
• Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ 1988; 926: 313–6
   Google Scholar
• Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med 1989; 321: 129–35
   PubMedGoogle Scholar
• Hansson L, Zanchetti A, Carruthers S, Dahiof B, Elmfeldt D, Julius S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755–62
   PubMed Web of Science ®Google Scholar
• Thrombosis prevention trial: randomized trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. Lancet 1998; 351: 233–41
   Google Scholar
• Hass WK, Easton JD, Adams HP, Jr., Pryse-Phillips W, Molony BA, Anderson S. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med 1989; 321: 501–7
   PubMed Web of Science ®Google Scholar
• Savonitto S, Ardissino D, Granger C, Morando G, Prando M, Mafrici A. Prognostic value of the admission electrocardiogram in acute coronary syndromes. JAMA 1999; 281: 707–13
   PubMed Web of Science ®Google Scholar
• Lewis H, Davis J, Archibald D, Steinke W, Smitherman T, Doherty J. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. N Engl J Med 1983; 309: 396–403
   PubMed Web of Science ®Google Scholar
• Cairns J, Gent M, Singer J, Finnie K, Froggatt G, Holder D. Aspirin, sulfinpyrazone, or both in unstable angina: Results of a Canadian multicenter trial. N Engl J Med 1985; 313: 1369–75
   PubMed Web of Science ®Google Scholar
• Theroux P, Quimet H, McCans J, Latour J, Joly P, Levy G. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988; 319: 1105–11
   PubMed Web of Science ®Google Scholar
• Wallentin LC. Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. Research Group on Instability in Coronary Artery Disease in Southeast Sweden. J Am Coll Cardiol 1991; 18: 1587–93
   PubMed Web of Science ®Google Scholar
• Balsano F, Rizzon P, Violi F, Scrutinio D, Cimminiello C, Aguglia F. Antiplatelet treatment with ticlopidine in unstable angina: a controlled multicenter clinical trial. The studio della Ticlopidina nell'Angina Instabile Group. Circulation 1990; 82: 17–26
   PubMed Web of Science ®Google Scholar
• Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. PRISM-PLUS Study Investigators. N Engl J Med 1998; 338: 1488–97
   PubMedGoogle Scholar
• Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein Ilb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 1998; 339: 436–43
   PubMedGoogle Scholar
• International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network. Circulation 1998; 97: 2386–95
   PubMedGoogle Scholar
• A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. N Engl J Med 1998; 338: 1498–505
   PubMed Web of Science ®Google Scholar
• Lincoff A, Califf R, Topol E. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease. J Am Coll Cardiol 2000; 35: 1103–15
   PubMed Web of Science ®Google Scholar
• Randomised placebo-controlled trial of abciximab before and during coronary interventions in refractory unstable angina: the CAPTURE Study. Lancet 1997; 349: 1429–35
   PubMed Web of Science ®Google Scholar
• Ryan T, Anderson J, Antman E, Braniff B, Brooks N, Califf R. ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1996; 28: 1328–428
   PubMed Web of Science ®Google Scholar
• Baigent C, Collins R, Appleby P, Parish S, Sleight P, Peto R. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. BMJ 1998; 316: 1337–43
   PubMed Web of Science ®Google Scholar
• Roux S, Christeller S, Luedin E. Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: a meta-analysis. J Am Coll Cardiol 1992; 19: 671–7
   PubMed Web of Science ®Google Scholar
• Simes R, Topol E, Holmes DJ, White H, Rutsch W, Vahanian A. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. Circulation 1995; 91: 1923–8
   PubMed Web of Science ®Google Scholar
• Falk E. Thrombosis in unstable angina: pathologic aspects. Cardiovasc Clin 1987; 18: 137–49
   PubMedGoogle Scholar
• Zhu Y, Carmeliet P, Fay W. Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance. Circulation 1999; 99: 3050–5
   PubMed Web of Science ®Google Scholar
• Antman EM, Giugliano RP, Gibson CM, McCabe CH, Coussement P, Kleiman NS. Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 Trial. The TIMI 14 Investigators. Circulation 1999; 99: 2720–32
   PubMed Web of Science ®Google Scholar
• Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. Circulation 2000; 101: 2788–94
   PubMed Web of Science ®Google Scholar
• Serruys PW, Strauss BH, Beatt KJ, Bertrand ME, Puel J, Rickards AF. Angiographic follow-up after placement of a self-expanding coronary artery stent. N Engl J Med 1991; 324: 13–7
   PubMed Web of Science ®Google Scholar
• Schwartz L, Bourassa MG, Lesperance J, Aldridge HE, Kazim F, Salvatori VA. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988; 318: 1714–9
   PubMed Web of Science ®Google Scholar
• Lembo N, Black A, Roubin G, Wilentz J, Mufson L, Douglas JJ. Effect of pretreatment with aspirin versus aspirin plus dipyridamole on frequency and type of acute complications of percutaneous transluminal coronary angioplasty. Am J Cardiol 1990; 65: 422–6
   PubMed Web of Science ®Google Scholar
• Barnathan ES, Schwartz JS, Taylor L, Lasky W, Kleaveland JP, Kussmaul WG. Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty. Circulation 1987; 76: 125–34
   PubMed Web of Science ®Google Scholar
• Rupprecht H-J, Darius H, Borkowski U, Voigtlander T, Nowak B, Genth S. Comparison of antiplatelet effects of aspirin, ticlopidine, or their combination after stent implantation. Circulation 1998; 97: 1046–52
   PubMed Web of Science ®Google Scholar
• Quinn M, Fitzgerald D. Ticlopidine and clopidogrel. Circulation 1999; 100: 1667–72
   PubMed Web of Science ®Google Scholar
• Urban P, Macaya C, Rupprecht HJ, Kiemeneij F, Emanuelsson H, Fontanelli A. Randomized evaluation of anticoaguiation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation 1998; 98: 2126–32
   PubMed Web of Science ®Google Scholar
• Bertrand ME, Legrand V, Boland J, Fleck E, Bonnier J, Emmanuelson H. Randomized multicenter comparison of conventional anticoaguiation versus antiplatelet therapy in unplanned and elective coronary stenting. The Full Anticoaguiation Versus Aspirin and Ticlopidine (FANTASTIC) Study. Circulation 1998; 98: 1597–603
   PubMed Web of Science ®Google Scholar
• Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KKL. A clinical trial comparing three anti-thrombotic regimens following coronary-artery stenting. Stent Anti-coagulation Restenosis Study Investigators. N Eng J Med 1998; 339: 1665–71
   PubMed Web of Science ®Google Scholar
• Schomig A, Neumann F-J, Kastrati A, Schuhlen H, Blasini R, Hadamitzky M. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Eng J Med 1996; 334: 1084–9
   PubMed Web of Science ®Google Scholar
• Cadroy Y, Bossavy J, Thalamas C, Sagnard L, Sakariassen K, Boneu B. Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans. Circulation 2000; 101: 2823–8
   PubMed Web of Science ®Google Scholar
• Mueller C, Buettner H, Petersen J, Roskamm H. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents. Circulation 2000; 101: 590–3
   PubMed Web of Science ®Google Scholar
• Taniuchi M, Kurz H, Smith S, Lasala J. Ticlid or plavix post-stent (TOPPS): randomization to 2 weeks of treatment. Am J Cardiol 1999; 84: 68P–9P, (Suppl 6A)
   Web of Science ®Google Scholar
• Morris D. Results from late-breaking clinical trials sessions at ACCIS 99 and ACC 99. J Am Coll Cardiol 1999; 34: 1–8
   PubMed Web of Science ®Google Scholar
• Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med 1997; 336: 1689–96
   PubMedGoogle Scholar
• Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998; 352: 87–92
   PubMedGoogle Scholar
• Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention. IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet 1997; 349: 1422–8
   PubMedGoogle Scholar
• Brener SJ, Barr LA, Burchenal E, Katz S, George BS, Jones AA. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 1998; 98: 734–41
   PubMed Web of Science ®Google Scholar
• Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994; 330: 956–61
   PubMedGoogle Scholar
• Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. Circulation 1997; 96: 1445–53
   PubMed Web of Science ®Google Scholar
• Bach R, Jung F, Kohsiek I, Ozbek C, Spitzer S, Scheller B. Factors affecting the restenosis rate after percutaneous translumina… coronary angioplasty. Thromb Res 1994; 74: S55–67
   PubMed Web of Science ®Google Scholar
• Acute platelet inhibition with abciximab does not reduce instent restenosis (ERASER Study). The Eraser Investigators. Circulation 1999; 100: 799–806
   PubMedGoogle Scholar